ICMH
EUCRU

Integrity Capital Management (HK)’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Integrity Capital Management (HK)’s Portfolio EUCRU Stock Details EUCRU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,800
Closed -$37K – 72
2022
Q1 		$37K Buy
+3,800
New +$37.7K 0.19% 94

Other funds holding EUCRU

Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
CIM
Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return
SMA
Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Integrity Capital Management (HK)'s EUCRU Position: Q2 2022 in Review

Integrity Capital Management (HK) sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q2 2022, closing a stake of 3,800 shares — an estimated $37K sold.

Integrity Capital Management (HK) first reported a position in EUCRU in Q1 2022 and held it in 1 quarter. The position peaked at $37K in Q1 2022. 17 funds tracked by Wall St. Rank hold EUCRU as of Q2 2022.

  • Integrity Capital Management (HK) reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q2 2022 after selling out during the quarter.
  • Integrity Capital Management (HK) sold 3,800 Eucrates Biomedical Acquisition Corp. Unit shares in Q2 2022, an estimated $37K.
  • Integrity Capital Management (HK) first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q1 2022 and held it in 1 quarter.
  • Integrity Capital Management (HK)'s Eucrates Biomedical Acquisition Corp. Unit position peaked at $37K in Q1 2022.
  • 17 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q2 2022.

Based on Integrity Capital Management (HK)'s 13F filing for Q2 2022.